Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

5BS0

MAGE-A3 Reactive TCR in complex with Titin Epitope in HLA-A1

5BS0 の概要
エントリーDOI10.2210/pdb5bs0/pdb
関連するPDBエントリー5brz
分子名称HLA class I histocompatibility antigen, A-1 alpha chain, Beta-2-microglobulin, Titin, ... (8 entities in total)
機能のキーワードimmuno pmhc tcr titin, immune system
由来する生物種Homo sapiens (Human)
詳細
細胞内の位置Membrane; Single-pass type I membrane protein: P30443
Secreted : P61769
Cytoplasm : Q8WZ42
Membrane ; Single-pass membrane protein : P01848
タンパク質・核酸の鎖数5
化学式量合計94367.25
構造登録者
主引用文献Raman, M.C.,Rizkallah, P.J.,Simmons, R.,Donnellan, Z.,Dukes, J.,Bossi, G.,Le Provost, G.S.,Todorov, P.,Baston, E.,Hickman, E.,Mahon, T.,Hassan, N.,Vuidepot, A.,Sami, M.,Cole, D.K.,Jakobsen, B.K.
Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy.
Sci Rep, 6:18851-18851, 2016
Cited by
PubMed Abstract: Natural T-cell responses generally lack the potency to eradicate cancer. Enhanced affinity T-cell receptors (TCRs) provide an ideal approach to target cancer cells, with emerging clinical data showing significant promise. Nevertheless, the risk of off target reactivity remains a key concern, as exemplified in a recent clinical report describing fatal cardiac toxicity, following administration of MAGE-A3 specific TCR-engineered T-cells, mediated through cross-reactivity with an unrelated epitope from the Titin protein presented on cardiac tissue. Here, we investigated the structural mechanism enabling TCR cross-recognition of MAGE-A3 and Titin, and applied the resulting data to rationally design mutants with improved antigen discrimination, providing a proof-of-concept strategy for altering the fine specificity of a TCR towards an intended target antigen. This study represents the first example of direct molecular mimicry leading to clinically relevant fatal toxicity, mediated by a modified enhanced affinity TCR designed for cancer immunotherapy. Furthermore, these data demonstrate that self-antigens that are expressed at high levels on healthy tissue should be treated with extreme caution when designing immuno-therapeutics.
PubMed: 26758806
DOI: 10.1038/srep18851
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.4 Å)
構造検証レポート
Validation report summary of 5bs0
検証レポート(詳細版)ダウンロードをダウンロード

249697

件を2026-02-25に公開中

PDB statisticsPDBj update infoContact PDBjnumon